Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wiese

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Journal of Medicinal Chemistry|December 13, 2002
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis)Ilza K Pajeva, Michael Wiese
Medicinal Research Reviews|May 30, 2018
Small-molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advancesSven Marcel Stefan, Michael Wiese
The AAPS Journal|June 9, 2009
Structure-activity relationships of tariquidar analogs as multidrug resistance modulatorsIlza K Pajeva, Michael Wiese
Expert Opinion on Therapeutic Patents|April 29, 2014
HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616)Michael Wiese, Ilza K Pajeva
Journal of Medicinal Chemistry|April 10, 2015
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)Sebastian C Köhler, Michael Wiese
Medicinal Research Reviews|April 4, 2019
The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation-a case study of multidrug resistance-associated protein 1 (ABCC1)Michael Wiese, Sven Marcel Stefan
Journal of Medicinal Chemistry|May 6, 2016
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)Michael K Krapf, Michael Wiese
Arthritis Care & Research|January 13, 2025
ReplyDorsa Maher, Emily Reeve, Michael Wiese
Pflege Zeitschrift|April 2, 2005
[Clinical treatment pathways--1: High quality at low cost--an incompatible goal conflict?]Tina Küttner, Michael Wiese, Norbert Roeder
Pflege Zeitschrift|May 13, 2005
[Clinical treatment pathways--2: The path is the goal--and an optimized organizational methodology]Tina Küttner, Michael Wiese, Norbert Roeder
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|December 13, 2002
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis)Ilza K Pajeva, Michael Wiese
Medicinal Research Reviews|May 30, 2018
Small-molecule inhibitors of multidrug resistance-associated protein 1 and related processes: A historic approach and recent advancesSven Marcel Stefan, Michael Wiese
The AAPS Journal|June 9, 2009
Structure-activity relationships of tariquidar analogs as multidrug resistance modulatorsIlza K Pajeva, Michael Wiese
Expert Opinion on Therapeutic Patents|April 29, 2014
HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616)Michael Wiese, Ilza K Pajeva
Journal of Medicinal Chemistry|April 10, 2015
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)Sebastian C Köhler, Michael Wiese
Medicinal Research Reviews|April 4, 2019
The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation-a case study of multidrug resistance-associated protein 1 (ABCC1)Michael Wiese, Sven Marcel Stefan
Journal of Medicinal Chemistry|May 6, 2016
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)Michael K Krapf, Michael Wiese
Arthritis Care & Research|January 13, 2025
ReplyDorsa Maher, Emily Reeve, Michael Wiese
Pflege Zeitschrift|April 2, 2005
[Clinical treatment pathways--1: High quality at low cost--an incompatible goal conflict?]Tina Küttner, Michael Wiese, Norbert Roeder
Pflege Zeitschrift|May 13, 2005
[Clinical treatment pathways--2: The path is the goal--and an optimized organizational methodology]Tina Küttner, Michael Wiese, Norbert Roeder
Pageof 12